Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denifanstat in Noncirrhotic MASH and F2/F3 Fibrosis
NCT06594523Phase 3Withdrawn
- Sponsor
- Sagimet Biosciences
- Start
- Mar 2025
- Primary completion
- Dec 2030
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of denifanstat in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Sagimet Biosciences. Planned start Mar 2025; status: withdrawn.
02
Drugs
denifanstat
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT06594523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06594523.